VolitionRx Limited Temporary Equity, Foreign Currency Translation Adjustments
VolitionRx Limited (VNRX) reported Temporary Equity, Foreign Currency Translation Adjustments of $141.69 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Shareholders' Equity
us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments · last filed 2025-03-31
- VolitionRx Limited temporary equity, foreign currency translation adjustments for the quarter ending 2024-12-31 was $245.36K.
- VolitionRx Limited temporary equity, foreign currency translation adjustments for the quarter ending 2024-09-30 was -$141.98K, a 553.74% decline year-over-year.
- VolitionRx Limited temporary equity, foreign currency translation adjustments for the quarter ending 2024-06-30 was $23.29K, a 38.25% decline year-over-year.
- VolitionRx Limited temporary equity, foreign currency translation adjustments for the quarter ending 2024-03-31 was $15.03K.
- VolitionRx Limited temporary equity, foreign currency translation adjustments for fiscal 2024 was $141.69K, a 741.25% increase from fiscal 2023.
- VolitionRx Limited temporary equity, foreign currency translation adjustments for fiscal 2023 was $16.84K, a 78.62% decline from fiscal 2022.
- VolitionRx Limited temporary equity, foreign currency translation adjustments for fiscal 2022 was $78.77K, a 62.18% decline from fiscal 2021.
- VolitionRx Limited temporary equity, foreign currency translation adjustments for fiscal 2021 was $208.30K.
| Period end | Temporary Equity, Foreign Currency Translation Adjustments 3 month | Temporary Equity, Foreign Currency Translation Adjustments 6 month | Temporary Equity, Foreign Currency Translation Adjustments 9 month | Temporary Equity, Foreign Currency Translation Adjustments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $245.36K derived: 10-K 12 month − 3 quarters · filed 2025-03-31 | $103.38K derived: sum of 2 quarters · filed 2025-03-31 | $126.67K derived: sum of 3 quarters · filed 2025-03-31 | $141.69K 10-K · filed 2025-03-31 |
| 2024-09-30 | -$141.98K 10-Q · filed 2024-11-14 | -$118.69K derived: sum of 2 quarters · filed 2024-11-14 | -$103.67K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2024-06-30 | $23.29K 10-Q · filed 2024-11-14 | $38.31K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2024-03-31 | $15.03K 10-Q · filed 2024-11-14 | |||
| 2023-12-31 | $16.84K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $31.29K 10-Q · filed 2024-11-14 | $69.00K derived: sum of 2 quarters · filed 2024-11-14 | $12.53K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $37.71K 10-Q · filed 2024-11-14 | -$18.77K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | -$56.48K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $78.77K 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $71.03K 10-Q · filed 2023-11-14 | $285.12K derived: sum of 2 quarters · filed 2023-11-14 | $167.22K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $214.10K 10-Q · filed 2023-11-14 | $96.19K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | -$117.90K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $208.30K 10-K · filed 2023-03-15 | |||
| 2021-09-30 | -$20.88K 10-Q · filed 2022-11-14 | -$65.42K derived: sum of 2 quarters · filed 2022-11-14 | $68.71K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$44.55K 10-Q · filed 2022-11-14 | $89.58K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $134.13K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | -$185.65K 10-K · filed 2022-03-30 | |||
| 2020-09-30 | -$573.40K 10-Q · filed 2020-11-12 | -$647.72K derived: sum of 2 quarters · filed 2020-11-12 | -$273.79K derived: sum of 3 quarters · filed 2021-05-11 | |
| 2020-06-30 | -$74.32K 10-Q · filed 2020-11-12 | $299.61K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2020-03-31 | $373.93K 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$97.98K 10-K · filed 2021-03-22 | |||
| 2019-09-30 | $401.31K 10-Q · filed 2020-11-12 | $451.22K derived: sum of 2 quarters · filed 2020-11-12 | $427.17K derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $49.91K 10-Q · filed 2020-11-12 | $25.86K derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | -$24.05K 10-Q · filed 2020-11-12 | |||
| 2018-12-31 | $352.99K 10-K · filed 2020-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |